Ono Pharma's ONO-1110 misses primary endpoints in three Phase 2 pain studies
Bitget2026/10/29 03:03- Ono Pharmaceutical today announced plans for further ONO-1110 studies in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis following pain-improvement signals.
- All three Phase 2 trials missed their primary endpoints; subgroup and exploratory analyses suggested pain relief.
- No further studies are planned in major depressive disorder or social anxiety disorder, where trials showed no efficacy signals.
- ONO-1110 demonstrated a favorable safety profile across all five studies.
- Detailed results will be presented at future conferences and through other appropriate channels.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
